Funder: National Institutes of Health (NIH)
Due Dates: November 21, 2024 (final) | Rolling prior dates until November 21, 2024
Funding Amounts: Up to $350,000 direct costs per year for up to 2 years; requires 25% non-federal cost match
Summary: Supports early-stage translational research to identify lead compound series for developing therapeutics targeting heart, lung, blood, and sleep (HLBS) diseases and disorders.
Key Information: Clinical trials are not allowed; applications must include an Accelerator Partner and cost-matching letters; strong emphasis on milestones and project management.